Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab
| Autor: | Amitkumar, Pande, Jeffrey, Lombardo, Edward, Spangenthal, Milind, Javle |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Aged 80 and over Male Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factor Receptor-1 Neovascularization Pathologic Incidence Antibodies Monoclonal Angiogenesis Inhibitors Middle Aged Antibodies Monoclonal Humanized Vascular Endothelial Growth Factor Receptor-2 United States Bevacizumab Hypertension Humans Female Protein Kinase Inhibitors Aged |
| Zdroj: | Anticancer research. 27(5B) |
| ISSN: | 0250-7005 |
| Popis: | Hypertension (HT) is a common complication of anti-angiogenic therapy. Its incidence, treatment and complications are undefined.Retrospective review of patients treated with bevacizumab (BV) from 2003-5. Common toxicity criteria (CTC) for adverse events version 3.0 were used.Fifty-five out of the 154 patients treated with BV (35%) experienced HT. Eleven (20%) developed a new onset HT and 44 (80%) experienced an exacerbation of pre-existing HT. HT developed after a median of 11 weeks at a median BV dose of 10 mg/kg. HT severity was grade 1 (n =1), grade 2 (n=29) or grade 3 (n=22); 3 experienced hypertensive complications. HT was controlled in 47 (85%); BV was discontinued in 3. The angiotensin-converting enzyme inhibitor (ACE-I), quinapril was commonly used and resulted in better HT control than ACE-II, calcium channel or beta antagonists.HT associated with bevacizumab therapy is a manageable toxicity with the use of ACE-I. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|